Interim safety data for lentiviral gene delivery shows encouraging progress for wet AMD and Stargardt’s

Oxford Biomedica, a public gene therapy company focused on lentiviral gene delivery, has announced the receipt of a positive interim review for two gene therapy studies in ophthalmic disease from the Data Safety & Monitoring Board (DSMB). The two experimental products include “RetinoStat”, a product designed to deliver two anti-angiogenic genes (angiostatin and endostatin) to the retina for the treatment of wet AMD and, “StarGen”, a product designed to deliver a corrected version of the ABCR gene for the treatment of Stargardt’s disease. Both therapeutic approaches are delivered by lentiviral vectors derived from a sub-class of retroviruses with the unique capability to infect non-dividing cells.